Anna Berkenblit Highlights Promising KRAS Vaccine Data in Pancreatic Cancer
Anna Berkenblit, Chief Scientific and Medical Officer at Pancreatic Cancer Action Network, shared a post on X:
“Encouraging early results from Elicio Therapeutics KRAS-targeting vaccine in pancreatic cancer and colorectal cancer published in
Nature Medicine, feat. co-corresponding authors/PanCAN SMAB members, Dr. Shubham Pant and Eileen M O’Reilly.
The development of an “off-the-shelf” vaccine approach targeting mutant KRAS is particularly compelling in pancreaticcancer, where new therapeutic strategies are urgently needed.
While these results are preliminary, further studies will be critical to determine durability, safety, and clinical benefit across broader patient populations.
At PanCAN, we continue to emphasize the importance of clinical trial participation at every treatment decision point. Patients and families seeking guidance can connect with PanCAN Patient Services for a personalized clinical trial search.”
Title: Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results
Authors: Zev A. Wainberg, Colin D. Weekes, Muhammad Furqan, Pashtoon M. Kasi, Craig E. Devoe, Alexis D. Leal, Vincent Chung, James R. Perry, Thian Kheoh, Lisa K. McNeil, Esther Welkowsky, Peter C. DeMuth, Christopher M. Haqq, Shubham Pant, Eileen M. O’Reilly
Read the Full Article.
More posts featuring Pancreatic Cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023